Ablation Rates and Long-Term Outcome Following Low-Dose Radioiodine for Differentiated Thyroid Cancer in the West of Scotland: A Retrospective Analysis
Authors' conclusion
Remnant ablation was achieved in >90%, and the corresponding clinical recurrence rate was only 1.8% despite the inclusion of patients with locally advanced disease. Low-dose radioiodine is effective and may be suitable for a proportion of patients with higher-risk DTC.
Study context
- Population
- Patients with low- to intermediate-risk differentiated thyroid cancer (DTC) receiving low-dose RAI for remnant ablation, January 1, 2012, to December 31, 2014; median age 43 years (range, 14 to 80 years); T3 27%, T4 2.5%109 with dual response assessment
- Participants
- 114 patients
- Outcome
- Successful ablation: Iodine-131 uptake <0.1% on diagnostic scan and Tg <2.0 ng/mL
- Follow-up
- 6 to 8 months after treatment
Methodological detailssingle-institution, Follow-up annually for 10 years
- Single-institution
- Follow-up annually for 10 years
Main finding
As reported in the abstract
Ablation success
Ablation success on diagnostic scan alone
94.7%
108/114
Ablation success on Tg alone
94.7%
108/114
Ablation success on both modalities
90.4%
103/114
Observational data: associations, not effects.
Further findings
- Involved lymph nodes detected
- 21% (N1a 8% and N1b 13%)
- Nodal staging performed in just over 30%
Original publication
Ablation Rates and Long-Term Outcome Following Low-Dose Radioiodine for Differentiated Thyroid Cancer in the West of Scotland: A Retrospective Analysis. Endocr Pract. Published 5 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →